Ho­mol­o­gy cleared to re­sume gene ther­a­py tri­al for rare meta­bol­ic dis­ease af­ter FDA lifts hold

A few months af­ter get­ting the stop sign from the FDA, Ho­mol­o­gy Med­i­cines is now able to restart its Phase II tri­al of a gene ther­a­py for the rare meta­bol­ic dis­ease phenylke­tonuria, or PKU.

The FDA had shown con­cerns that Ho­mol­o­gy’s gene ther­a­py, known as HMI-102, might lead to liv­er dam­age is­sues. In an­nounc­ing the hold had been lift­ed, Ho­mol­o­gy said there were no hos­pi­tal­iza­tions re­quired per­tain­ing to the el­e­vat­ed liv­er func­tion tests seen in the tri­al of adults.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER